お問い合わせ
-
各種お問い合わせはこちらから www.quantiferon.com/jp/contact-us/
The COVID-19 pandemic is negatively impacting TB testing services
International efforts have succeeded in slowing the COVID-19 pandemic, but responding to COVID-19 has also forced disruption of TB control programs around the globe. Such disruption may reverse between 5 and 8 years of progress against TB, with a recent report released by Stop TB suggesting the potential for an additional 1.4 million tuberculosis deaths by 2025, due to COVID-19-related disruption to TB prevention services (1).
Are you providing testing and treatment for patients at increased risk?
The WHO and the ECDC recommend systematic latent TB testing for those at increased risk, including (2):
1. Adults, adolescents, children and infants living with HIV
2. Infants and children <5 years who are contacts of TB patients
3. Patients initiating anti-TNF treatment, receiving dialysis, preparing for organ or hematological transplantation
Learn more about TB testing for key risk groups:
-
HIV and TB testing
Learn more about TB testing for immunocompromised patients.
Download the brochure -
Biologics and TB
Learn why TB testing is critical prior to receiving TNF inhibitor therapy.
Download the brochure -
Contact Tracing
Deploy rapid and accurate contact investigation in response to emerging TB cases.
Download the brochure
References
1. Stop TB Partnership in collaboration with Imperial College, Avenir Health, Johns Hopkins University and USAID. The potential impact of the COVID-19 response on tuberculosis in high-burden countries: a modeling analysis.
2. WHO. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment.
